CTLA4 and autoimmune disease: Not surprisingly, CTLA-4 mutations or polymorphisms have been observed in patients with autoimmune diseases and patients with Efavirenz and nonsteroidal anti-inflammatory drug hypersensitivity (210, 211, 228, 229), suggesting CTLA-4 alteration may disrupt homeostatic function, resulting in the observed disease phenotype.